Pınar Gürsoy Öner

9PUBLICATIONS
95CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursClinical midwifery
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Dec 11, 2025
Clinicopathologic Determinants of Lymph Node Count and Prognostic Significance of Metastatic Lymph Node Ratio in Colorectal Cancer.

Fatma Yildirim, Murat Sezak, Osman Bozbiyik

|Nov 17, 2025
Real-world comparison of doxorubicin-ifosfamide versus gemcitabine-docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study.

Salih Tunbekici, Gokhan Sahin, Haydar Cagatay Yuksel

|Oct 30, 2023
Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.

Sumru Sozer Karadagli, Pınar Gursoy

|May 31, 2022
Avascular necrosis during alectinib treatment: Case report.

Pınar Gürsoy

|Apr 06, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.

Pınar Gursoy, Ali Murat Tatli, Dilek Erdem

Pageof 2

Frequent Collaborators

3 joint publications

Erdem Goker

2 joint publications

Evrican Zin

2 joint publications

Mustafa Seyyar

2 joint publications

Aytac Terzi